Clin Osteol 2012; 17(3): 76-83

Osteonecrosis of the jaw associated with bisphospohonate therapy - practical experiencesOriginal contributions

Šenk F., Jirgl L.

At present, bisphosphonates (BPs) are the most common group of antiresorptive drugs used in the treatment of numerous metabolic bone diseases, especially postmenopausal osteoporosis. Adverse effects of these drugs include the risk of development of osteonecro­ sis of the jaw. This dental complication is relatively frequent in intravenous therapy with high doses of BPs in malignancies associated with high bone resorption and hypercalcemia. The article deals with the risk of development of this complication even after admini­ stration of oral BPs in bone disorders to patients at risk of developing osteonecrosis, e.g. due to old age, prolonged exposure to BPs and systemic corticosteroid therapy.

Keywords: bisphosphonates, bone disease, osteonecrosis ofthejaw, corticosteroids

Published: December 11, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šenk F, Jirgl L. Osteonecrosis of the jaw associated with bisphospohonate therapy - practical experiences. Osteologický bulletin. 2012;17(3):76-83.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Treister NS, Woo SB. Bisphosphonate-associated osteonecrosis of the jaw. In: Rosen C, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Seventh Ed. John Wiley and Sons, 2009; pp.505-509. Go to original source...
    2. Cvek J, Dvořáčková J, Gruna J, Hodan R. Osteonekróza čelistí u onkologicky ne­ mocných. Remedia 2010; 10:338-342.
    3. Marx RE et al. Pamindronate (Aredia) and zoledronate (Zometa) induced avascu­ lar necrosis ofjaw: a growing epidemic. J Oral Maxillofac Surg 2003;1115-1117. Go to original source...
    4. Ruggiero SL et al. Osteonecrosis of the jaws associated with the use of bisphos­ phonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-534. Go to original source...
    5. Hauer L, Hrušák D, Hostička L, Andrle P, Jambora J, Pošta P. Osteonekróza če­ listí v souvislosti s celkovou léčbou bisfosfonáty - dop. pro praxi. LKS 2011;21(5): 94-105.
    6. Hodan R, Mendreková M, Cvek J, Gruna J. Prevence osteonekrózy čelisti před on­ kologickou léčbou. Onkologie 2009;3(1):62-65.
    7. Estefania Fresco R, Ponte Fernández R, Aguirre Urizar JM. Bisphosphonates and Oral Pathology II. Osteonecrosis of the jaws: Review of the literature before 2005. Med Oral Patol Oral Cir Bucal 2006;11:E456-61.
    8. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-Induced Exposed Bone (Osteonecrosis/Osteopetrosis) of the Jaws: Risk Factors, Recognition, Prevention, and Treatment. J Oral Maxillofac Surg 2005;63:1567-1575. Go to original source...
    9. American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws. Update 2009.
    10. Serra MP, Llorca CS, Silvestre Donat SFJ. Oral implants in patients receiving bisphosphonates: A review and update. Med Oral Patol Oral Cir Bucal 2008;13(12):E755-60.
    11. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum treatment. CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007;65(12):2397-2410. Go to original source...
    12. Kunchur R, Need A, Hughes T, Goss A. Clinical investigation of C-terminal cross­ linking telopeptide test in prevention and management of bisphosphonate-asso­ ciated osteonecrosis of the jaws. J Oral Maxillofac Surg 2009;67(6):1167-1173. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.